These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12042842)

  • 1. Genta strikes bumper deal with Aventis.
    Dorey E
    Nat Biotechnol; 2002 Jun; 20(6):533-4. PubMed ID: 12042842
    [No Abstract]   [Full Text] [Related]  

  • 2. Sense and antisense for investors.
    Jacobs T
    Nat Biotechnol; 2002 Jun; 20(6):543. PubMed ID: 12042846
    [No Abstract]   [Full Text] [Related]  

  • 3. Isis and antisense face crucial test without Novartis.
    Dove A
    Nat Biotechnol; 2000 Jan; 18(1):19. PubMed ID: 10625379
    [No Abstract]   [Full Text] [Related]  

  • 4. AIDS and the private sector.
    Nature; 2006 Oct; 443(7113):723. PubMed ID: 17051166
    [No Abstract]   [Full Text] [Related]  

  • 5. Firms seek new models to access public equity.
    Mitchell P
    Nat Biotechnol; 2009 Oct; 27(10):878-9. PubMed ID: 19816432
    [No Abstract]   [Full Text] [Related]  

  • 6. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 7. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 8. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public sector seeks to bridge 'valley of death'.
    Moran N
    Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
    [No Abstract]   [Full Text] [Related]  

  • 10. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.
    Wheeler C
    Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech's wellspring--a survey of the health of the private sector in 2014.
    Huggett B
    Nat Biotechnol; 2015 May; 33(5):470-7. PubMed ID: 25965753
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 14. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics. After the gold rush: gene firms reinvent themselves.
    Gura T
    Science; 2002 Sep; 297(5589):1982-4. PubMed ID: 12242421
    [No Abstract]   [Full Text] [Related]  

  • 16. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

  • 17. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug benefits for seniors and public/private collaboration.
    Brekke M
    Beginnings; 2002; 22(3):11. PubMed ID: 12046112
    [No Abstract]   [Full Text] [Related]  

  • 19. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
    Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
    Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does the public sector have an independent research role in the development of drugs?].
    Poulsen HE; Grønlykke TB
    Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.